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classified according to the categories of Chow (IJROBP, 
2012). 
Results: 248 consecutive patients (Male/Female: 144/104; 
median age: 68 years;range:27-94 years) were included in the 
study. On the basis of radiological exams and CT simulation, 
86% of the patients (214/248) had no extra-osseous extension 
compared to 14% (24/248) that presented bone disease with 
involvement of the adjacent soft tissues. All the patients 
were symptomatic for pain at the time of treatment. Three 
weeks later, 44% of the patients (109/248) showed pain 
reduction or resolution. In detail, 58 patients (23.5%) 
obtained a complete response (CR), 51 (20.5%) a partial 
response (PR), 63 (25%) no response to treatment (pain 
worsening) and 76 (30%) had an unspecified response. A 
statistically significant pain reduction was reported (pre- vs 
post-RT mean VAS: 4.6 versus 3.7; p=0.0001). CR rate (table 
1, p:0.678) as well CR+PR rate (p:0.274) were not 
significantly associated with extra-osseous extension. 
 
 
 
Conclusions: The efficacy of 8 Gy single fraction schedule 
was confirmed in terms of pain control even in patients with 
bone metastases with extension to soft tissues. The relatively 
low analgesic response is likely due to the administering of 
analgesic drugs before irradiation in the majority of cases. 
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Purpose/Objective: To evaluate and to compare the 
dosimetric features of static and volumetric intensity-
modulated radiotherapy (IMRT) for brain oligometastases 
hypofractionated stereotactic treatment, focusing on the 
dosimetric comparison between the single and multiple 
isocenters modalities for multiple contiguous brain 
metastases.  
Materials and Methods: Patients with single or multiple brain 
metastases, in the same lobe or contiguous, treated by 
hypofractionated stereotactic RT in our Institution were 
enrolled. For each patient 2 treatment plans were 
performed: a static (5 fields) and a volumetric (2 arcs) IMRT 
plans. For patient with multiple brain metastases, each plan 
was performed in 2 different modalities: single and multiple 
isocenters. The PTV was the lesion + 3 mm. In single 
isocentre modality plans, for patients with multiple lesions, 
the definitive PTV was the PTV sum of each single lesion. The 
prescribed dose to lesions was 25.5 Gy/3fr. Plans were 
evaluated for: monitor units (UM); Conformity Index (CI); 
Homogeneity Index (HI); Paddick Conformity Index (PCI); 
Gradient Index (GI); normal brain mean dose; brainstem, 
optic chiasm, optic nerves maximum dose; EQD2 
hyppocampus mean dose. Dose-volume histograms were 
compared by Friedman test. 
Results: Thirteen patients were included in the analysis, 7 
patients with a solitary lesion, 6 patients with multiple (2-3) 
metastases in the same lobe or contiguous, with a total of 20 
treated lesions. The median CTV was 0.71 cm3 (range, 0.21-
5.26), median PTV was 4.7 cm3 (range, 1.5-18.47). Median 
mean dose to normal brain tissue was 1.79 (0.68-6.27) for 
volumetric IMRT and 1.92 (0.69-8.70) for static IMRT (p: 
0.024). Among the 6 oligometastatic patients, a total of 13 
lesions was analyzed. For multiple isocenters modality plans 
median CTV was 0.53 cm3 (0.21-3.27), median PTV was 3.64 
cm3 (1.49-18.47). For single isocentre modality median CTV 
was 1.59 cm3 (0.47-5.95), median PTV 10.68 cm3 (2.99-
27.08). Median mean dose to normal brain tissue was 3.72 
(1.80-5.84) and 3.52 (2.49-5.67) for static IMRT in single and 
multiple modality, respectively, 3.84 (2.41-6.27) and 3.22 
(2.02-5.31) for volumetric IMRT in single and multiple 
isocentre modality, respectively (p:0.009). Median GI for 
static IMRT plans was 1.62 (1.40-2.05) and 1.50 (1.30-1.70) in 
single and multiple isocentre modality respectively, 1.60 
(1.25-1.95) and 1.35 (1.15-1.60) for volumetric IMRT plans in 
single and multiple isocentre modality respectively (p: 
0.024). None of the other studied parameters resulted in 
significant differences.  
Conclusions: In our experience static and volumetric IMRT 
are both efficient techniques for intensity modulated 
hypofracionated stereotactic treatment. Volumetric IMRT 
seems to results in lower normal brain dose in single 
isocenter modality; multiple isocenters modality seems to 
reduce normal brain irradiation in treating multiple 
contiguous lesions.  
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Purpose/Objective: Stereotactic Ablative Body Radiotherapy 
(SABR) has emerged as a novel treatment modality for local 
extracranial metastases such as lymph node oligometastases 
with promising clinical results. This study aims to investigate 
the relationship between dosimetric parameters of SABR and 
treatment outcomes for patients with unresectable nodal 
metastases. 
Materials and Methods: A retrospective review of SABR 
patients who were treated using a Cyberknife unit at our 
institution was carried out to determine each patient's 
Progression Free Survival (PFS) and Overall Survival (OS). 
Patient's demographic data including age, anatomical 
location of sites treated and histopathology of primary 
disease were reviewed. Assuming a/ß=10 for tumour control, 
dosimetric parameters including biological equivalent doses 
(BED) of prescription dose, minimum dose and mean dose to 
GTV and PTV (GTVmin, GTVmean, PTVmin and PTVmean) 
